Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Trial Profile

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Pegfilgrastim
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2022 Planned End Date changed from 30 Jun 2023 to 1 Sep 2023.
    • 30 Jul 2021 Primary endpoint has been met. (The completion rate of chemotherapy in combination with chemoradiation), as per Results published in the Clinical Cancer Research
    • 30 Jul 2021 Results assesing relationship between ctDNA and clinical outcomes and feasiblity and rate of pCR for neoadjuvant FOLFIRINOX followed by chemoradiation, published in the Clinical Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top